Please assess the completion status of the following clinical trial:

Trial Title: Irinotecan Plus Cisplatin vs Pemetrexed Plus Cisplatin as 2nd Line in NSCLC Stage IIIB/IV

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically or cytologically confirmed NSCLC~* Age 18 -75 years~* Performance status (WHO) \<2~* Patients progressing after first-line docetaxel/gemcitabine treatment~* Adequate bone marrow (absolute neutrophil count \>1000/mm3, platelet count \>100000/mm3, hemoglobin \> 9 gr/ mm3)~* Adequate liver (bilirubin \<1.5 times upper limit of normal), renal (Creatinine clearance \> 50mg/min) and cardiac (LVEF \>50%) function~* Presence of measurable disease (according to RESIST criteria)~* Informed consent~Exclusion Criteria:~* Psychiatric illness or social situation that would preclude study compliance'~* Other concurrent uncontrolled illness.~* Other invasive malignancy within the past 5 years except nonmelanoma skin cancer

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): IC
- 2 (Type: EXPERIMENTAL): PC

Based on this trial design, predict the completion outcome and termination type (if applicable).